These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 9626464)

  • 1. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
    Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
    Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone.
    Schumaker L; Nikitakis N; Goloubeva O; Tan M; Taylor R; Cullen KJ
    Clin Cancer Res; 2008 Sep; 14(18):5877-83. PubMed ID: 18794100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.
    Blanchet A; Bourgmayer A; Kurtz JE; Mellitzer G; Gaiddon C
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.
    Wu S; He H; Liu H; Cao Y; Li R; Zhang H; Li H; Shen Z; Qin J; Xu J
    Oncoimmunology; 2018; 7(6):e1433517. PubMed ID: 29872564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
    Meulendijks D; Rozeman EA; Cats A; Sikorska K; Joerger M; Deenen MJ; Beijnen JH; Schellens JHM
    Pharmacogenomics J; 2017 Oct; 17(5):441-451. PubMed ID: 27995989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
    Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.
    Xu HY; Xu WL; Wang LQ; Chen MB; Shen HL
    PLoS One; 2014; 9(4):e95371. PubMed ID: 24740294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers.
    Rotblat B; Grunewald TG; Leprivier G; Melino G; Knight RA
    Oncotarget; 2013 Dec; 4(12):2577-90. PubMed ID: 24342878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.
    Tulsyan S; Chaturvedi P; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
    Mol Diagn Ther; 2013 Dec; 17(6):371-9. PubMed ID: 23812950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
    Choi IS; Lee HS; Lee KW; Kim H; Kim KH; Kim YJ; Kim JH; Kim WH; Lee JS
    Med Oncol; 2011 Dec; 28(4):991-8. PubMed ID: 20533001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
    Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
    Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
    Yeh CN; Jung SM; Chen TW; Hwang TL; Jan YY; Chen MF
    Langenbecks Arch Surg; 2010 Mar; 395(3):217-25. PubMed ID: 20012317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
    Raab R; Sparano JA; Ocean AJ; Christos P; Ramirez M; Vinciguerra V; Kaubisch A
    Am J Clin Oncol; 2010 Feb; 33(1):61-5. PubMed ID: 19738454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
    Showalter SL; Showalter TN; Witkiewicz A; Havens R; Kennedy EP; Hucl T; Kern SE; Yeo CJ; Brody JR
    Cancer Biol Ther; 2008 Jul; 7(7):986-94. PubMed ID: 18443433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.
    Kamoshida S; Suzuki M; Shimomura R; Sakurai Y; Komori Y; Uyama I; Tsutsumi Y
    Br J Cancer; 2007 Jan; 96(2):277-83. PubMed ID: 17211470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers for gastric adenocarcinoma: an update.
    Anderson C; Nijagal A; Kim J
    Mol Diagn Ther; 2006; 10(6):345-52. PubMed ID: 17154651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
    Ichikawa W
    Gastric Cancer; 2006; 9(3):145-55. PubMed ID: 16952032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.
    Moureau-Zabotto L; Ricci S; Lefranc JP; Coulet F; Genestie C; Antoine M; Uzan S; Lotz JP; Touboul E; Lacave R
    Br J Cancer; 2006 Feb; 94(4):473-80. PubMed ID: 16434992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
    Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
    Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
    Ichikawa W; Takahashi T; Suto K; Yamashita T; Nihei Z; Shirota Y; Shimizu M; Sasaki Y; Hirayama R
    Br J Cancer; 2004 Oct; 91(7):1245-50. PubMed ID: 15354215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.